3.99
+0.01(+0.25%)
Currency In USD
| Previous Close | 3.98 |
| Open | 3.96 |
| Day High | 4.11 |
| Day Low | 3.94 |
| 52-Week High | 7.08 |
| 52-Week Low | 2.61 |
| Volume | 351,696 |
| Average Volume | 1.14M |
| Market Cap | 506.38M |
| PE | -49.87 |
| EPS | -0.08 |
| Moving Average 50 Days | 4.46 |
| Moving Average 200 Days | 4.37 |
| Change | 0.01 |
If you invested $1000 in Organogenesis Holdings Inc. (ORGO) since IPO date, it would be worth $409.23 as of February 21, 2026 at a share price of $3.99. Whereas If you bought $1000 worth of Organogenesis Holdings Inc. (ORGO) shares 5 years ago, it would be worth $311.48 as of February 21, 2026 at a share price of $3.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and
Organogenesis Announces Initiation of Biologics License Application for ReNu®
GlobeNewswire Inc.
Dec 23, 2025 9:05 PM GMT
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on t
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
GlobeNewswire Inc.
Dec 15, 2025 9:25 PM GMT
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the dev